Welcome to LookChem.com Sign In|Join Free

CAS

  • or

909849-01-0

Post Buying Request

909849-01-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

909849-01-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 909849-01-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,9,8,4 and 9 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 909849-01:
(8*9)+(7*0)+(6*9)+(5*8)+(4*4)+(3*9)+(2*0)+(1*1)=210
210 % 10 = 0
So 909849-01-0 is a valid CAS Registry Number.

909849-01-0Relevant articles and documents

Synthesis and Structure-Activity Relationships of the Novel Antimalarials 5-Pyridinyl-4(1 H)-Pyridones

Bueno, José M.,Calderon, Félix,Chicharro, Jesús,De La Rosa, Juan C.,Díaz, Beatriz,Fernández, Jorge,Fiandor, José M.,Fraile, María T.,García, Mercedes,Herreros, Esperanza,García-Pérez, Adolfo,Lorenzo, Milagros,Mallo, Araceli,Puente, Margarita,Saadeddin, Anas,Ferrer, Santiago,Angulo-Barturen, I?igo,Burrows, Jeremy N.,León, María L.

, p. 3422 - 3435 (2018/05/01)

Malaria is still one of the most prevalent parasitic infections in the world, with half of the world's population at risk for malaria. The effectiveness of current antimalarial therapies, even that of the most recent class of antimalarial drugs (artemisin

Discovery, synthesis, and optimization of antimalarial 4(1 H)-quinolone-3-diarylethers

Nilsen, Aaron,Miley, Galen P.,Forquer, Isaac P.,Mather, Michael W.,Katneni, Kasiram,Li, Yuexin,Pou, Sovitj,Pershing, April M.,Stickles, Allison M.,Ryan, Eileen,Kelly, Jane Xu,Doggett, J. Stone,White, Karen L.,Hinrichs, David J.,Winter, Rolf W.,Charman, Susan A.,Zakharov, Lev N.,Bathurst, Ian,Burrows, Jeremy N.,Vaidya, Akhil B.,Riscoe, Michael K.

, p. 3818 - 3834 (2014/05/20)

The historical antimalarial compound endochin served as a structural lead for optimization. Endochin-like quinolones (ELQ) were prepared by a novel chemical route and assessed for in vitro activity against multidrug resistant strains of Plasmodium falciparum and against malaria infections in mice. Here we describe the pathway to discovery of a potent class of orally active antimalarial 4(1H)-quinolone-3-diarylethers. The initial prototype, ELQ-233, exhibited low nanomolar IC50 values against all tested strains including clinical isolates harboring resistance to atovaquone. ELQ-271 represented the next critical step in the iterative optimization process, as it was stable to metabolism and highly effective in vivo. Continued analoging revealed that the substitution pattern on the benzenoid ring of the quinolone core significantly influenced reactivity with the host enzyme. This finding led to the rational design of highly selective ELQs with outstanding oral efficacy against murine malaria that is superior to established antimalarials chloroquine and atovaquone.

ANTIMALARIAL COMPOUNDS

-

Page/Page column 50, (2012/06/15)

The present invention relates to antimalarial compounds. More specifically, the present invention relates to novel substituted quinolone derivatives of formula (I) and related quinoline derivatives of formula (II) as defined herein that possess potent ant

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 909849-01-0